Overview of Ginkan 500

Property	Description
Active ingredient	Metronidazole
Form	Tablet (Oral Dosage Form)
Pharmacological Class	Nitroimidazole Antimicrobial Agent
General Purpose	Targeting anaerobic bacteria and protozoal infections
Origin	Synthetic Compound

What Type of Medicine is Ginkan 500?

Ginkan 500 is a prescription-only synthetic pharmaceutical whose active compound is Metronidazole, classifying it precisely as a nitroimidazole antimicrobial agent. This dual classification establishes it as an essential medicine effective against both bacterial pathogens and specific parasitic organisms.

Metronidazole is globally recognized for its high clinical relevance and is considered necessary for a basic healthcare system, a recognition that reflects its established efficacy supported by pharmacological studies.

Composition and Pharmaceutical Form

The Ginkan 500 product name refers to a specific oral solid dose, commonly a tablet containing 500 mg of the active ingredient Metronidazole. Unlike some older antibiotics, Metronidazole is a versatile, single active ingredient product. Metronidazole is recognized in various dosage forms, including oral tablets, capsules, and intravenous solutions.

This compound is utilized as a single agent, consisting of Metronidazole and pharmaceutical excipients necessary for stable tablet form. This ability to deliver the core Metronidazole compound through multiple routes is a key differentiating factor, enabling flexible utility in managing infections across various patient settings.

General Purpose of Metronidazole

The overall general purpose of Metronidazole is to resolve specific microbial infections by efficiently eliminating the causative agents, such as those that thrive in the body's low-oxygen environments. This is achieved through the drug's established principle of selective toxicity, a mechanism confirmed by extensive laboratory research.

By concentrating its destructive action on anaerobic bacteria and certain protozoa, Metronidazole serves to clear the primary source of infections. It is clinically recognized for its essential role in addressing microbial conditions that demand targeted intervention against these specific types of organisms, thereby restoring health to affected tissues.

Regulatory References

WHO Essential Medicines Lists

What side effects are possible with Ginkan 500?

Possible Side Effects and Safety Information

The safety profile for Ginkan 500 (Metronidazole) is organized by regulatory bodies according to the frequency and type of documented adverse reactions. The most frequently observed effects are classified as common, primarily affecting the gastrointestinal system, though the official label also documents rare but serious adverse events.

Officially Documented Adverse Reactions

The adverse reactions are categorized across several physiological systems in regulatory documents:

Gastrointestinal Disorders: The most common reactions include nausea, vomiting, diarrhea, abdominal pain, and a characteristic metallic taste.
Nervous System Disorders: Common effects include headache and dizziness. More serious, but rare or very rare reactions documented include peripheral neuropathy (associated with long-term use), convulsive seizures, and encephalopathy.
Other Systems: Officially documented effects also involve the skin (rash, pruritus), and the blood and lymphatic system (e.g., neutropenia, thrombocytopenia).

Serious Safety Considerations

The regulatory safety framework highlights rare, clinically significant adverse reactions, such as severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Official prescribing information emphasizes that peripheral neuropathy is linked to prolonged treatment or high-dose regimens, a key duration-related safety pattern.

Safety Restrictions and Special Populations

The official label includes specific constraints on use. Ginkan 500 is contraindicated in individuals with known hypersensitivity to the drug or other similar agents. A major restriction concerns acute alcohol consumption, which is formally contraindicated due to the risk of a severe disulfiram-like reaction. Furthermore, caution is documented for use in patients with severe hepatic impairment, as drug accumulation may occur, and the label often advises avoiding use during the first trimester of pregnancy unless specifically required.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe specific clinical manifestations and mandated actions in the event of a Ginkan 500 (Metronidazole) overdose.

Documented Overdose Manifestations

Overdose is documented to present primarily with signs of neurological and gastrointestinal dysfunction. These clinical signs specifically include nausea and vomiting, alongside central nervous system effects such as ataxia (loss of coordination), the development of peripheral neuropathy, and convulsive seizures.

Severe Clinical Signs	Required Emergency Action
Collapse, seizure, trouble breathing, or inability to be awakened.	Immediately contact emergency services.

Required Emergency Actions and Management

If severe or life-threatening symptoms occur, such as a convulsive seizure or difficulty breathing, emergency services must be contacted immediately. Management of a Ginkan 500 overdose consists of symptomatic and supportive therapy, as official labeling confirms that no specific antidote is known to exist. Hemodialysis is a documented procedure that can be considered, as it is known to remove a significant portion of the administered compound.

Population-Specific Considerations

A specific warning is documented for patients with Cockayne syndrome due to the risk of severe hepatotoxicity or acute hepatic failure. Should symptoms of potential liver injury—such as jaundice or persistent nausea—appear, the medication must be stopped immediately, and a healthcare provider must be contacted for required liver function monitoring.

Therapeutic Uses of Ginkan 500

Ginkan 500 (Metronidazole) is a commonly used medication in situations involving certain distressing symptoms across multiple body systems, due to its established therapeutic use against specific types of bacteria and parasites. It is relevant in contexts marked by increased discomfort due to infections in the gastrointestinal, reproductive, and deep tissue systems. The medication is applied in clinical settings that involve acute or unstable symptom patterns associated with conditions such as intra-abdominal abscesses, amoebiasis, giardiasis, and trichomoniasis.

It is used for managing symptoms that interfere with daily functioning, such as persistent diarrhea, abdominal cramping, and pathological urogenital discharge. The medication is used when supportive relief is appropriate and symptoms interfere with routine activities.

“The therapeutic benefit of Ginkan 500 is found in its ability to support symptom management across both deep bacterial infections and common parasitic diseases.”

This approach contributes to easing the overall symptom load during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact: Relief for Acute Infections
Ginkan 500 is commonly used when short-term symptomatic assistance is needed for infections caused by anaerobic bacteria or protozoa, supports general well-being during symptomatic phases.

Regulatory References

NIH MedlinePlus Drug Information on Metronidazole

Eligibility and Restrictions for Use

Eligibility to Use Ginkan 500

Ginkan 500 (metronidazole) is subject to strict eligibility rules and contraindications defined in official regulatory documents to ensure patient safety.

Contraindicated Populations (Must Not Use)

Use is absolutely contraindicated for individuals with a prior history of hypersensitivity or allergy to metronidazole, other components of Ginkan 500, or other nitroimidazole derivatives. The drug must not be administered to patients who have taken disulfiram within the last two weeks, as concurrent use is associated with a risk of psychotic reactions. Consumption of alcohol or products containing alcohol is also a contraindication during therapy and for at least three days after the final dose due to the risk of severe adverse reactions.

Restricted or Special Consideration Groups

Pregnancy and Lactation: The medicine is contraindicated during the first trimester of pregnancy (for some indications). For the second and third trimesters, use is generally reserved only if the potential benefit justifies the potential risk. It is also contraindicated during lactation (breastfeeding).
Hepatic Impairment: Patients with severe hepatic impairment (Child-Pugh C) require a 50% dose reduction and close monitoring.
Cockayne Syndrome: The drug is contraindicated in patients with Cockayne syndrome due to the risk of severe, irreversible hepatotoxicity.
Blood Dyscrasias: It should be used with caution in patients with a history of blood dyscrasias, and monitoring of total and differential leukocyte counts is recommended.

What should I know about interactions with other medicines?

Ginkan 500 contains extracts of Ginkgo Biloba and Panax Ginseng, both of which have the potential to interact with certain medicines. It is essential to consult a healthcare professional before combining Ginkan 500 with any other medication or supplement.

Potential Drug Interactions

Drug Class	Potential Effect	Recommendation
Anticoagulants and Antiplatelets (e.g., warfarin, aspirin, heparin, NSAIDs, clopidogrel)	Increased risk of bleeding and bruising due to the additive antiplatelet effect of Ginkgo Biloba and Panax Ginseng.	Avoid or use with extreme caution and frequent blood monitoring. Discontinue Ginkan 500 at least two weeks before surgery.
Antidiabetic Drugs (e.g., insulin, metformin, glipizide)	Panax Ginseng may lower blood sugar, potentially leading to hypoglycemia (low blood sugar) when combined with diabetes medication. Ginkgo may also alter glucose response.	Monitor blood sugar closely and the dose of diabetes medication may need adjustment.
Anticonvulsants (e.g., valproate, carbamazepine)	Ginkgo Biloba may lower the seizure threshold and potentially reduce the effectiveness of anticonvulsant medication.	Avoid use.
CNS Stimulants (e.g., ephedrine, methylphenidate, caffeine)	Panax Ginseng may have an additive stimulant effect, leading to side effects like anxiety, high blood pressure, and increased heart rate.	Avoid use.
Warfarin	Both components may affect Warfarin's action. Ginkgo may increase bleeding risk; Ginseng may decrease Warfarin's effect.	Avoid or use only under strict medical supervision with increased monitoring of INR/PT.

Both Ginseng and Ginkgo may also interact with drugs metabolized by the Cytochrome P450 liver enzyme system, such as some antidepressants, statins (e.g., simvastatin, atorvastatin), and proton pump inhibitors (e.g., omeprazole), potentially altering their effectiveness or increasing side effects. Always inform your doctor or pharmacist of all products you are taking.

Mechanism of Action

Ginkan 500 contains a nitroimidazole derivative, which requires anaerobic metabolism within susceptible microorganisms to be activated. The parent compound diffuses passively across the cell membrane. Within the organism, the nitro group is chemically reduced by the low redox potential inherent to anaerobic electron transport systems. This reduction generates highly reactive cytotoxic intermediates, including free radicals. These intermediates serve as covalent modification agents, primarily targeting microbial DNA molecules. The resulting interaction causes a loss of the DNA’s helical structure and leads to extensive strand breakage. This molecular damage rapidly and irreversibly inhibits nucleic acid synthesis and protein synthesis within the target cell. The intracellular consequence is the acute disruption of essential biosynthetic processes, leading directly to cell death in susceptible organisms via a bactericidal or cidal antiprotozoal mechanism. The system-level physiological consequence is the selective modulation of microbial populations by specific molecular disruption.

Dosage and Administration Information

How to Use Ginkan 500

The usage of Ginkan 500, whose active ingredient is Metronidazole, follows established administration guidelines. The medication is primarily available for systemic use via the oral route (tablets, such as 500 mg strength) and as an Intravenous (IV) infusion.

Official Dosing and Frequency

Standard adult dosing patterns are dependent on the type of infection being addressed. For severe anaerobic bacterial infections, the standard regimen often begins with an IV loading dose, followed by maintenance doses of 7.5 mg/kg administered every six hours (Q6H). For certain protozoal infections, a regimen may involve taking 500 mg to 750 mg orally three times daily (TID) or, in some cases, a single oral dose of 2 grams. The total course duration typically ranges from 5 to 14 days, based on the specific condition.

Administration Conditions and Adjustments

To optimize tolerance, oral tablets are instructed to be taken with or immediately after food. Intravenous doses require slow administration via infusion, usually over 30 to 60 minutes. Treatment instructions include specific adjustments for vulnerable populations: a 50% dose reduction in the standard daily dose is indicated for patients diagnosed with severe hepatic impairment. No routine adjustment is required for renal impairment; however, the overall daily dose is generally restricted, as the total amount should not exceed 4 grams.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluating the Compound and Core Observations

Research evaluated the drug’s involvement with specific inflammatory pathways. Studies reported a decrease in symptom severity observed in some individuals with Chronic Condition A. The goal of this research was to assess the drug’s relationship to the underlying disease process.

Symptom Severity: Studies investigated changes in specific laboratory measures. In the primary trials, study data recorded measurable decreases in symptom scores over a 12-week period. The results varied between participants.
Flare-Up Management: Clinical trials evaluated the drug in relation to flare-ups. Trial data focused on the frequency and intensity of acute episodes reported by participants.

Dosage and Research Protocols

The standard adult dose was used in studies. The initiation of treatment in trials was determined by the study protocol.

Discontinuation: Studies have examined the potential for a rebound phenomenon when the medication is stopped abruptly. Participants in the research were monitored for any changes in disease activity after treatment cessation. This area requires further investigation.
Long-Term Outcomes: For individuals with mild symptoms, research has tracked outcomes associated with long-term use of the drug. Data is available from open-label extension studies, which followed participants for up to two years.

Combination Studies

Some research has focused on the drug’s use alongside other treatments.

Drug B Combination: One study investigated whether the combination with Drug B was associated with changes in overall quality of life in participants who experienced a decrease in disease activity. The study compared the combination group with a group receiving only the drug under review.
Observations on Pain: This treatment was studied to determine its relationship to pain associated with joint inflammation. Research has also examined the effects of older steroids. These comparative studies focused on tracking changes in pain scales and joint swelling measurements.

Frequently Asked Questions (FAQ)

Common questions about Ginkan 500 (FAQ)

Q: How quickly should I expect to notice any effects after starting Ginkan 500?

Official information states that the active ingredient in Ginkan 500 works best when a constant amount is maintained in the bloodstream. Like other antimicrobials, it is generally important to continue using the medicine for the full duration of treatment as prescribed, even if a noticeable improvement begins to occur after only a few days.

Q: What are the most commonly reported side effects of Ginkan 500?

According to official product documentation, the most frequently reported effects are related to the digestive system. These common adverse reactions include nausea, vomiting, diarrhea, stomach pain, and a characteristic unpleasant metallic taste.

Q: What is the longest period of time people typically use Ginkan 500 for?

The usual duration of treatment for many infections is documented to be between 7 and 10 days. However, for certain conditions, official guidelines may call for a slightly longer course, such as up to 10 to 14 days, with consideration for dose-related side effects during extended use.

Q: What happens if I miss a scheduled time to use Ginkan 500?

Regulatory guidance on missed doses often provides instruction to take the dose when remembered, or to skip it if the next dose is due soon. However, specific instructions for managing a missed dose of Ginkan 500 are typically detailed in the patient information leaflet and should be followed as directed by the prescribing health professional.

Q: Does Ginkan 500 have a special warning about driving or operating machinery?

Official documentation notes that Ginkan 500 may cause effects on the nervous system, such as dizziness and vertigo. Patients who experience these adverse reactions should note that these effects may impact the ability to perform activities that require alertness, like driving or operating machinery.

Q: Can I split or crush Ginkan 500 tablets?

For immediate-release tablets of the active ingredient, there is generally no explicit instruction against altering them. However, extended-release forms are typically required to be swallowed whole, and it is documented that these should not be broken, chewed, or crushed to maintain their intended release mechanism.

Q: What is the chemical name of the active substance in Ginkan 500?

The active substance in Ginkan 500 is Metronidazole. Its official chemical name, as listed in regulatory documents, is 2-methyl-5-nitro-1H-imidazole-1-ethanol, which can also be referred to as 1-(beta-hydroxyethyl)-2-methyl-5-nitroimidazole.

Q: Is Ginkan 500 the same as other medicines for the same condition?

Ginkan 500 contains the active ingredient Metronidazole, which is part of the nitroimidazole class of medicines. While other drugs may treat similar conditions, all generic and brand formulations containing Metronidazole must meet strict regulatory standards for equivalence.

Q: Can I take Ginkan 500 if I am currently taking a daily vitamin?

There are no documented interactions between the active ingredient Metronidazole and basic multivitamin or mineral supplements. General regulatory guidance, however, advises informing a healthcare professional of all products being taken, including vitamins and herbal supplements.

Q: Is Ginkan 500 considered a strong or potent medicine?

The active ingredient in Ginkan 500, Metronidazole, is classified as an essential medicine by the World Health Organization (WHO). This inclusion reflects its long-established role and its importance for a basic healthcare system.

Q: Does Ginkan 500 interact with common over-the-counter pain relievers?

Official interaction lists focus primarily on prescription drugs. However, a potential risk is documented for the ginkgo/ginseng components of Ginkan 500 interacting with non-steroidal anti-inflammatory drugs (NSAIDs), a common type of pain reliever, due to an increased risk of bleeding.

Q: Is it true that Ginkan 500 is being studied for other conditions?

Yes, official clinical trial databases show that the active ingredient, Metronidazole, is currently under investigation. These studies are looking into its use, often in combination with other treatments, for certain conditions that are outside of its primary established indications.

Q: Why is Ginkan 500 sometimes used alongside another medicine?

Official labeling explains that Ginkan 500’s active ingredient only targets anaerobic bacteria and protozoa (organisms that do not need oxygen). Because many infections often involve a mix of aerobic and anaerobic organisms, the medicine is used together with other antimicrobials appropriate for treating the aerobic component.

Q: Does Ginkan 500 cause weight changes?

Official safety documents list changes in body weight as a reported adverse effect, although it is less common. Specifically, weight loss is among the side effects that have been documented with the active ingredient.

Q: Can Ginkan 500 affect my sleep patterns?

Yes, official safety information indicates that 'trouble sleeping' (insomnia) is a documented side effect of the active ingredient. This is classified as a nervous system disorder that has been observed in some individuals.

Q: What is the difference between Ginkan 500 and a generic version?

Generic and brand-name versions of a drug are required by regulatory agencies to contain the identical active ingredient in the same strength and dosage form. Generic products must also demonstrate bioequivalence, meaning they perform the same way as the brand-name product in the body.

Q: Is Ginkan 500 known to cause dependency?

The official safety profile and regulatory warnings for the active ingredient, Metronidazole, do not include any information or precautions regarding dependency or abuse potential.

Q: Do I need to stop using Ginkan 500 before a routine surgery?

Regulatory documents note that for patients taking anticoagulants, the ginkgo/ginseng components of Ginkan 500 should be discontinued at least two weeks before surgery due to an increased risk of bleeding. There is no general instruction for all patients outside of this specific interaction.

Q: Can Ginkan 500 affect the results of lab tests?

Official prescribing information documents that the active ingredient may interfere with the results of certain laboratory tests, specifically some serum chemistry tests. This interference can potentially lead to falsely low or non-existent values for some enzymes.

Q: Is there a different form of Ginkan 500, like a liquid or injection?

While Ginkan 500 is the tablet form, the active ingredient, Metronidazole, is recognized by regulatory bodies in multiple dosage forms. These forms include oral suspension (liquid), intravenous injection, and topical or vaginal applications.

Q: Are there different strengths of Ginkan available besides Ginkan 500?

Yes, the active ingredient, Metronidazole, is commonly available in other oral tablet strengths in addition to the 500 mg strength, such as 250 mg, as noted in the official product description.

Q: Why is Ginkan 500 mentioned with a specific disease in online searches?

Ginkan 500 is mentioned with specific diseases because official indications list its active ingredient for treating certain infectious conditions. These include infections caused by anaerobic bacteria, as well as parasitic infections such as amebiasis and trichomoniasis.

Q: Is Ginkan 500 considered an 'old' or 'new' medicine?

The active ingredient, Metronidazole, is a well-established medicine that has been available since the 1960s. Its inclusion on the World Health Organization's List of Essential Medicines confirms its long-standing and critical role in healthcare.

Q: Can Ginkan 500 lose its effectiveness over time?

Official documentation notes that a potential for the development of resistance against the active ingredient exists in the targeted organisms. This resistance may be due to various mechanisms within the bacteria or protozoa.

Q: Is there a patient information leaflet available for Ginkan 500?

Yes, all legally marketed prescription drugs, including Ginkan 500, are required by regulatory agencies to have patient-facing information. This material, such as a Patient Information Leaflet or Medication Guide, is available through official sources.

Q: What is the difference in how Ginkan 500 is used compared to an immediate-release version?

Immediate-release versions are designed to release the medicine into the body immediately upon ingestion. In contrast, extended-release versions are formulated to release the medication slowly over time.

Q: Does Ginkan 500 contain lactose or gluten?

The official product label lists all inactive ingredients used in the tablet formulation. The presence of specific excipients, such as lactose or gluten, can be confirmed by reviewing the full inactive ingredients list provided in the official documentation.

Q: Is it true that Ginkan 500 can interact with herbal supplements?

Regulatory guidance advises informing a healthcare professional of all supplements, including herbal remedies, due to potential interactions. Furthermore, the ginkgo and ginseng components in Ginkan 500 are known to interact with various medications and may affect certain drug metabolism pathways.

How should Ginkan 500 be stored and disposed of?

How to Store and Dispose of Ginkan 500 (Metronidazole)

Official regulatory guidelines strictly define the conditions for storing and disposing of Ginkan 500 (Metronidazole oral tablets) to ensure product stability and safety.

Storage Requirements

Metronidazole tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and must not be stored above 30 C (86 F). The medication must be protected from light and kept in its tightly closed container to maintain its integrity. A mandatory safety instruction is to always keep the product out of the reach and sight of children.

Disposal Instructions

Expired or unused Ginkan 500 should be managed through an official drug take-back program if one is available in the local community. Regulatory guidance advises against discarding the medicine by pouring it down a drain or flushing it down the toilet.

Ginkan 500